[{"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-001", "question": "A 52-year-old woman with primary sclerosing cholangitis and ulcerative colitis presents with progressive fatigue and pruritus. Laboratory studies show alkaline phosphatase 892 U/L, total bilirubin 4.2 mg/dL, and CA 19-9 of 285 U/mL. MRCP reveals a dominant stricture at the hepatic duct bifurcation with upstream biliary dilation. Brush cytology obtained during ERCP shows atypical cells suspicious for malignancy. Fluorescence in situ hybridization (FISH) analysis demonstrates polysomy. Which additional finding on FISH would most strongly support a diagnosis of cholangiocarcinoma over reactive atypia in this clinical context?", "options": ["Homozygous deletion of 9p21 (CDKN2A/p16)", "Trisomy of chromosome 7", "Monosomy of chromosome 17", "Gain of chromosome 3", "Deletion of 1p36"], "answer": "A", "answer_index": 0, "explanation": "Homozygous deletion of 9p21 (CDKN2A/p16) detected by FISH has the highest specificity (approaching 100%) for cholangiocarcinoma in the setting of PSC with indeterminate biliary strictures. While polysomy alone increases suspicion for malignancy, it can occur in reactive conditions. Trisomy 7 and other chromosomal gains are less specific. The combination of polysomy plus 9p21 homozygous deletion essentially confirms malignancy in this high-risk population.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a PSC patient with a dominant stricture, elevated CA 19-9, and FISH showing polysomy with atypical cells—a classic high-risk scenario for cholangiocarcinoma. The question asks which additional FISH finding most strongly supports malignancy over reactive atypia. Key discriminating clue: the need for highest specificity to distinguish malignancy from benign reactive changes in PSC. Option A (homozygous 9p21/CDKN2A deletion) is well-established in literature as having near-100% specificity for cholangiocarcinoma when added to polysomy, making it the gold standard additional marker. Options B (trisomy 7), C (monosomy 17), and D (gain of chromosome 3) are components of polysomy but lack the specificity of homozygous 9p21 deletion. Option E (1p36 deletion) is not a standard FISH marker in this context. The keyed answer is medically accurate and uniquely defensible. No logical flaws or contradictions exist. Medical accuracy is excellent—reflects current understanding of FISH in PSC-associated cholangiocarcinoma diagnosis. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a PSC patient with a dominant stricture, elevated CA 19-9, and FISH showing polysomy with atypical cells—a classic high-risk scenario for cholangiocarcinoma. The question asks which additional FISH finding most strongly supports malignancy over reactive atypia. Key discriminating clue: the need for highest specificity to distinguish malignancy from benign reactive changes in PSC. Option A (homozygous 9p21/CDKN2A deletion) is well-established in literature as having near-100% specificity for cholangiocarcinoma when added to polysomy, making it the gold standard additional marker. Options B (trisomy 7), C (monosomy 17), and D (gain of chromosome 3) are components of polysomy but lack the specificity of homozygous 9p21 deletion. Option E (1p36 deletion) is not a standard FISH marker in this context. The keyed answer is medically accurate and uniquely defensible. No logical flaws or contradictions exist. Medical accuracy is excellent—reflects current understanding of FISH in PSC-associated cholangiocarcinoma diagnosis. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-002", "question": "A 38-year-old man undergoes evaluation for chronic diarrhea and weight loss. Small bowel biopsy reveals villous atrophy with increased intraepithelial lymphocytes. Despite strict gluten-free diet adherence confirmed by negative tissue transglutaminase antibodies for 18 months, symptoms persist. Repeat biopsy shows persistent villous atrophy with aberrant intraepithelial lymphocytes lacking surface CD3 but expressing cytoplasmic CD3, CD7, and CD103, with loss of CD8. T-cell receptor gene rearrangement studies show a monoclonal population. Which therapeutic approach offers the best chance of inducing remission before consideration of autologous stem cell transplantation?", "options": ["Budesonide 9 mg daily", "Cladribine-based chemotherapy", "Infliximab induction and maintenance", "Azathioprine 2.5 mg/kg daily", "Mesalamine 4.8 g daily"], "answer": "B", "answer_index": 1, "explanation": "This patient has Type II refractory celiac disease (RCD II), characterized by aberrant intraepithelial lymphocytes with the described immunophenotype (surface CD3-negative, cytoplasmic CD3-positive, CD8 loss) and monoclonal TCR rearrangement. RCD II has high risk of progression to enteropathy-associated T-cell lymphoma. Cladribine (2-CdA), a purine analog, has shown the best response rates (approximately 40-50%) in inducing histologic and clinical remission in RCD II and serves as a bridge to autologous stem cell transplantation. Steroids, immunomodulators, and biologics used in RCD I are ineffective in RCD II.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a 38-year-old man with initial celiac disease (villous atrophy, increased IELs) who remains symptomatic despite 18 months of confirmed gluten-free diet adherence (negative tTG antibodies). Key discriminating findings on repeat biopsy include aberrant intraepithelial lymphocytes with surface CD3-negative/cytoplasmic CD3-positive, loss of CD8, expression of CD7 and CD103, plus monoclonal T-cell receptor rearrangement. This immunophenotype definitively establishes Type II refractory celiac disease (RCD II), a premalignant condition with high risk of progression to enteropathy-associated T-cell lymphoma (EATL). The question explicitly asks for therapy before autologous stem cell transplantation consideration. Cladribine-based chemotherapy (B) is the established first-line treatment for RCD II, with documented response rates of 40-50% and serves as a bridge to ASCT. Option A (budesonide) may help RCD I but is ineffective in RCD II with monoclonal populations. Options C (infliximab) and D (azathioprine) lack evidence in RCD II. Option E (mesalamine) is for inflammatory bowel disease, not RCD II. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent, reflecting current specialized gastroenterology/hematology practice. Minimal fix: None needed; item is well-constructed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 38-year-old man with initial celiac disease (villous atrophy, increased IELs) who remains symptomatic despite 18 months of confirmed gluten-free diet adherence (negative tTG antibodies). Key discriminating findings on repeat biopsy include aberrant intraepithelial lymphocytes with surface CD3-negative/cytoplasmic CD3-positive, loss of CD8, expression of CD7 and CD103, plus monoclonal T-cell receptor rearrangement. This immunophenotype definitively establishes Type II refractory celiac disease (RCD II), a premalignant condition with high risk of progression to enteropathy-associated T-cell lymphoma (EATL). The question explicitly asks for therapy before autologous stem cell transplantation consideration. Cladribine-based chemotherapy (B) is the established first-line treatment for RCD II, with documented response rates of 40-50% and serves as a bridge to ASCT. Option A (budesonide) may help RCD I but is ineffective in RCD II with monoclonal populations. Options C (infliximab) and D (azathioprine) lack evidence in RCD II. Option E (mesalamine) is for inflammatory bowel disease, not RCD II. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent, reflecting current specialized gastroenterology/hematology practice. Minimal fix: None needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-003", "question": "A 45-year-old woman with lupus nephritis class IV on mycophenolate mofetil and prednisone develops acute kidney injury with serum creatinine rising from 1.2 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous dysmorphic RBCs, and RBC casts. Complement levels are normal and anti-dsDNA titers are stable. Kidney biopsy reveals crescentic glomerulonephritis with linear IgG staining along the glomerular basement membrane, with concurrent immune complex deposits in the mesangium. Anti-GBM antibodies are positive at 85 EU (normal <20). Which statement best characterizes this clinical entity?", "options": ["This represents lupus flare requiring intensification of immunosuppression alone", "The linear IgG staining is an artifact from prior immune complex deposition", "This is anti-GBM disease superimposed on lupus nephritis requiring plasmapheresis", "Concurrent ANCA-associated vasculitis is the most likely explanation", "The anti-GBM antibodies are false-positive due to cross-reactivity with dsDNA"], "answer": "C", "answer_index": 2, "explanation": "This patient has developed anti-GBM disease superimposed on pre-existing lupus nephritis, a rare but well-documented phenomenon. The linear IgG staining pattern is pathognomonic for anti-GBM disease and distinct from the granular pattern of lupus nephritis. The presence of positive anti-GBM antibodies confirms the diagnosis. Treatment requires plasmapheresis to remove circulating anti-GBM antibodies in addition to immunosuppression. Normal complements and stable anti-dsDNA argue against lupus flare as the sole explanation. Anti-GBM antibodies target the NC1 domain of type IV collagen and do not cross-react with dsDNA.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a patient with known lupus nephritis class IV who develops acute kidney injury with biopsy showing both linear IgG staining (pathognomonic for anti-GBM disease) and mesangial immune complex deposits (consistent with lupus nephritis), plus positive anti-GBM antibodies at 85 EU. Key discriminating findings: (1) linear IgG on IF with positive anti-GBM antibodies, (2) concurrent immune complex deposits, (3) normal complements and stable anti-dsDNA arguing against lupus flare, (4) crescentic GN with rapid creatinine rise. Option C correctly identifies this as dual pathology requiring plasmapheresis plus immunosuppression. Option A fails because normal complements/stable anti-dsDNA make pure lupus flare unlikely, and linear IgG pattern is not explained by lupus alone. Option B is incorrect—linear IgG is a distinct pathologic finding, not an artifact. Option D is unsupported (no ANCA mentioned, wrong IF pattern). Option E is medically inaccurate—anti-GBM antibodies target type IV collagen NC1 domain and do not cross-react with dsDNA. The item correctly tests recognition of rare dual pathology (anti-GBM disease superimposed on lupus nephritis) and appropriate management. Medical accuracy is excellent; the clinical scenario, pathologic findings, and treatment implications are all consistent with current nephrology literature. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a patient with known lupus nephritis class IV who develops acute kidney injury with biopsy showing both linear IgG staining (pathognomonic for anti-GBM disease) and mesangial immune complex deposits (consistent with lupus nephritis), plus positive anti-GBM antibodies at 85 EU. Key discriminating findings: (1) linear IgG on IF with positive anti-GBM antibodies, (2) concurrent immune complex deposits, (3) normal complements and stable anti-dsDNA arguing against lupus flare, (4) crescentic GN with rapid creatinine rise. Option C correctly identifies this as dual pathology requiring plasmapheresis plus immunosuppression. Option A fails because normal complements/stable anti-dsDNA make pure lupus flare unlikely, and linear IgG pattern is not explained by lupus alone. Option B is incorrect—linear IgG is a distinct pathologic finding, not an artifact. Option D is unsupported (no ANCA mentioned, wrong IF pattern). Option E is medically inaccurate—anti-GBM antibodies target type IV collagen NC1 domain and do not cross-react with dsDNA. The item correctly tests recognition of rare dual pathology (anti-GBM disease superimposed on lupus nephritis) and appropriate management. Medical accuracy is excellent; the clinical scenario, pathologic findings, and treatment implications are all consistent with current nephrology literature. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-004", "question": "A 62-year-old man with myelodysplastic syndrome with excess blasts-2 (MDS-EB2) undergoes allogeneic hematopoietic stem cell transplantation from a matched unrelated donor. On day +45, he develops progressive pancytopenia with WBC 0.8 × 10⁹/L, hemoglobin 7.2 g/dL, and platelets 12 × 10⁹/L. Bone marrow biopsy shows hypocellularity (10%) with no evidence of relapsed MDS. Chimerism analysis reveals 100% donor cells. Cytomegalovirus and HHV-6 PCR are negative. Which mechanism most likely explains this patient's graft failure?", "options": ["Donor-derived clonal hematopoiesis with DDX41 germline mutation", "Secondary hemophagocytic lymphohistiocytosis", "Graft-versus-host disease affecting the bone marrow stroma", "Residual host T-cell mediated rejection despite full donor chimerism", "Drug-induced marrow suppression from valganciclovir prophylaxis"], "answer": "A", "answer_index": 0, "explanation": "Donor-derived clonal hematopoiesis from germline mutations (particularly DDX41) in the donor can cause graft failure or donor-derived MDS/AML post-transplant. DDX41 mutations are increasingly recognized as a cause of familial MDS/AML and can be present in phenotypically normal donors. The 100% donor chimerism excludes host-mediated rejection. The absence of CMV/HHV-6 and the clinical context make drug toxicity less likely. HLH would typically show additional features (ferritin elevation, hepatosplenomegaly). Marrow stromal GVHD is rare and would not explain isolated hematopoietic failure with full donor chimerism.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes day +45 post-transplant pancytopenia with hypocellular marrow, 100% donor chimerism, and negative viral studies. Key discriminating findings: progressive pancytopenia, hypocellular marrow (10%), 100% donor chimerism, no MDS relapse, negative CMV/HHV-6. The keyed answer (A: donor-derived clonal hematopoiesis with DDX41) is theoretically possible but requires assuming the donor harbored a germline DDX41 mutation—a critical detail absent from the vignette. Without explicit mention of donor screening results, family history, or molecular testing, this diagnosis cannot be uniquely determined. Option C (marrow stromal GVHD) is equally defensible: while rare, it can cause isolated marrow failure with full donor chimerism and hypocellularity, fitting all provided findings. Option E (valganciclovir toxicity) is also plausible given the timing and pancytopenia pattern, though the stem doesn't confirm the patient received this drug. The item is underspecified because it lacks donor genetic information or drug exposure history needed to discriminate among these mechanisms. Main medical issue: DDX41-related donor-derived failure is an emerging concept but too specialized without explicit clues. Minimal fix: Add \\\"Donor genetic screening revealed heterozygous DDX41 germline mutation\\\" to uniquely support answer A.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes day +45 post-transplant pancytopenia with hypocellular marrow, 100% donor chimerism, and negative viral studies. Key discriminating findings: progressive pancytopenia, hypocellular marrow (10%), 100% donor chimerism, no MDS relapse, negative CMV/HHV-6. The keyed answer (A: donor-derived clonal hematopoiesis with DDX41) is theoretically possible but requires assuming the donor harbored a germline DDX41 mutation—a critical detail absent from the vignette. Without explicit mention of donor screening results, family history, or molecular testing, this diagnosis cannot be uniquely determined. Option C (marrow stromal GVHD) is equally defensible: while rare, it can cause isolated marrow failure with full donor chimerism and hypocellularity, fitting all provided findings. Option E (valganciclovir toxicity) is also plausible given the timing and pancytopenia pattern, though the stem doesn't confirm the patient received this drug. The item is underspecified because it lacks donor genetic information or drug exposure history needed to discriminate among these mechanisms. Main medical issue: DDX41-related donor-derived failure is an emerging concept but too specialized without explicit clues. Minimal fix: Add \"Donor genetic screening revealed heterozygous DDX41 germline mutation\" to uniquely support answer A.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-005", "question": "A 28-year-old woman presents with recurrent sinopulmonary infections since childhood, chronic diarrhea, and splenomegaly. Laboratory evaluation reveals IgG 180 mg/dL (normal 700-1600), IgA <7 mg/dL, IgM 320 mg/dL (normal 40-230), and absent isohemagglutinins. Flow cytometry shows normal B-cell numbers but absent CD27+ memory B cells. Genetic testing reveals a hemizygous mutation in CD40LG. Her brother has similar symptoms. Which finding would be most unexpected in this patient?", "options": ["Cryptosporidium parvum cholangiopathy", "Pneumocystis jirovecii pneumonia", "Germinal center formation on lymph node biopsy", "Neutropenia", "Elevated liver enzymes"], "answer": "C", "answer_index": 2, "explanation": "This patient has X-linked hyper-IgM syndrome (HIGM1) due to CD40LG mutation, which can occur in females due to skewed X-inactivation or homozygosity. CD40L-CD40 interaction is essential for germinal center formation, class-switch recombination, and somatic hypermutation. Therefore, germinal center formation would be absent on lymph node biopsy. Cryptosporidium cholangiopathy, PCP, neutropenia (due to impaired granulopoiesis), and elevated liver enzymes (from sclerosing cholangitis or hepatitis) are all well-documented complications of HIGM1.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - the question asks for the MOST UNEXPECTED finding, but the keyed answer (C) is actually the MOST EXPECTED finding to be absent. Key stem clues: 28-year-old woman with recurrent infections, low IgG/IgA, elevated IgM, absent CD27+ memory B cells, hemizygous CD40LG mutation, and affected brother establish X-linked hyper-IgM syndrome (HIGM1). The CD40L-CD40 interaction is essential for germinal center formation and class-switch recombination. Main logical issue: The question stem asks 'which finding would be most UNEXPECTED' but the keyed answer (absent germinal centers) is the MOST EXPECTED finding in HIGM1 - it is the pathognomonic feature. All other options (A-E) are well-documented complications that WOULD be expected in HIGM1 patients. The question logic is inverted. Main medical accuracy issue: The explanation correctly describes HIGM1 pathophysiology but contradicts the question stem's wording. If asking for 'most unexpected,' the answer should be something atypical for HIGM1, not its defining feature. Minimal fix: Change question to ask 'Which finding would be EXPECTED in this patient?' OR change the keyed answer to an option representing a finding NOT typically associated with HIGM1.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - the question asks for the MOST UNEXPECTED finding, but the keyed answer (C) is actually the MOST EXPECTED finding to be absent. Key stem clues: 28-year-old woman with recurrent infections, low IgG/IgA, elevated IgM, absent CD27+ memory B cells, hemizygous CD40LG mutation, and affected brother establish X-linked hyper-IgM syndrome (HIGM1). The CD40L-CD40 interaction is essential for germinal center formation and class-switch recombination. Main logical issue: The question stem asks 'which finding would be most UNEXPECTED' but the keyed answer (absent germinal centers) is the MOST EXPECTED finding in HIGM1 - it is the pathognomonic feature. All other options (A-E) are well-documented complications that WOULD be expected in HIGM1 patients. The question logic is inverted. Main medical accuracy issue: The explanation correctly describes HIGM1 pathophysiology but contradicts the question stem's wording. If asking for 'most unexpected,' the answer should be something atypical for HIGM1, not its defining feature. Minimal fix: Change question to ask 'Which finding would be EXPECTED in this patient?' OR change the keyed answer to an option representing a finding NOT typically associated with HIGM1.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-006", "question": "A 34-year-old man from the Ohio River Valley presents with 3 weeks of fever, night sweats, and 15-pound weight loss. He has a history of HIV infection with CD4 count of 45 cells/μL and is not on antiretroviral therapy. Physical examination reveals hepatosplenomegaly and diffuse lymphadenopathy. Laboratory studies show pancytopenia and LDH 1,850 U/L. Bone marrow biopsy reveals small intracellular yeast forms within macrophages. Urine Histoplasma antigen is strongly positive. He is started on liposomal amphotericin B. On day 3 of treatment, he develops high fever, hypotension, and worsening respiratory status despite negative blood cultures and improving fungal markers. Which intervention is most appropriate?", "options": ["Add voriconazole for possible amphotericin-resistant Histoplasma", "Initiate corticosteroids for immune reconstitution inflammatory syndrome", "Switch to itraconazole due to amphotericin B toxicity", "Add broad-spectrum antibiotics for bacterial superinfection", "Delay antiretroviral therapy initiation for at least 4 weeks"], "answer": "B", "answer_index": 1, "explanation": "This patient is experiencing paradoxical worsening consistent with immune reconstitution inflammatory syndrome (IRIS), which can occur in severely immunocompromised HIV patients even before ART initiation (unmasking IRIS) or represent early inflammatory response to effective antifungal therapy. The improving fungal markers argue against treatment failure or resistance. Corticosteroids (prednisone 0.5-1 mg/kg) are the treatment of choice for moderate-to-severe IRIS. While ART timing is important, the immediate management of IRIS takes precedence. Amphotericin B resistance in Histoplasma is exceedingly rare.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible)\\n\\nVerdict: Not uniquely determinable; both B and E are defensible.\\n\\nKey stem clues: Severely immunocompromised HIV patient (CD4=45) with disseminated histoplasmosis, started on amphotericin B, develops paradoxical worsening on day 3 with improving fungal markers. The vignette states he is \\\"not on antiretroviral therapy.\\\"\\n\\nMain logical issue: The stem is critically underspecified regarding whether ART has been initiated alongside amphotericin B. The explanation invokes \\\"unmasking IRIS\\\" or \\\"early inflammatory response,\\\" but classic IRIS requires immune reconstitution—typically from ART initiation. Day 3 is unusually early for IRIS without ART. If ART was started concurrently (unstated), option B (corticosteroids for IRIS) is reasonable. However, option E (delay ART ≥4 weeks) is equally defensible per current guidelines for disseminated histoplasmosis in advanced HIV, where ART is typically delayed 2-12 weeks to prevent IRIS. The stem does not clarify ART timing, making both interventions appropriate depending on that missing detail.\\n\\nMain medical accuracy issue: IRIS on day 3 without documented ART initiation is atypical. The explanation's \\\"unmasking IRIS\\\" concept is non-standard terminology.\\n\\nMinimal fix: Explicitly state whether ART was initiated with amphotericin B, or reframe the question to focus solely on managing established IRIS after documented ART start.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible)\n\nVerdict: Not uniquely determinable; both B and E are defensible.\n\nKey stem clues: Severely immunocompromised HIV patient (CD4=45) with disseminated histoplasmosis, started on amphotericin B, develops paradoxical worsening on day 3 with improving fungal markers. The vignette states he is \"not on antiretroviral therapy.\"\n\nMain logical issue: The stem is critically underspecified regarding whether ART has been initiated alongside amphotericin B. The explanation invokes \"unmasking IRIS\" or \"early inflammatory response,\" but classic IRIS requires immune reconstitution—typically from ART initiation. Day 3 is unusually early for IRIS without ART. If ART was started concurrently (unstated), option B (corticosteroids for IRIS) is reasonable. However, option E (delay ART ≥4 weeks) is equally defensible per current guidelines for disseminated histoplasmosis in advanced HIV, where ART is typically delayed 2-12 weeks to prevent IRIS. The stem does not clarify ART timing, making both interventions appropriate depending on that missing detail.\n\nMain medical accuracy issue: IRIS on day 3 without documented ART initiation is atypical. The explanation's \"unmasking IRIS\" concept is non-standard terminology.\n\nMinimal fix: Explicitly state whether ART was initiated with amphotericin B, or reframe the question to focus solely on managing established IRIS after documented ART start.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-007", "question": "A 58-year-old woman with metastatic HER2-positive breast cancer on trastuzumab deruxtecan develops progressive dyspnea over 4 weeks. CT chest reveals bilateral ground-glass opacities with a peripheral and lower lobe predominant distribution. Bronchoalveolar lavage shows lymphocytic predominance with CD4/CD8 ratio of 0.5. Infectious workup is negative. She is diagnosed with drug-induced interstitial lung disease. After drug discontinuation and corticosteroid initiation, her symptoms improve. Three months later, restaging shows disease progression. Which factor most strongly supports rechallenge with trastuzumab deruxtecan?", "options": ["Initial ILD grade was 1 with complete radiographic resolution", "Absence of anti-drug antibodies on serologic testing", "HER2 amplification ratio >6 on repeat biopsy", "Negative rechallenge skin testing to the drug", "Normal pulmonary function tests at baseline before rechallenge"], "answer": "A", "answer_index": 0, "explanation": "Rechallenge with trastuzumab deruxtecan after ILD is a complex decision. Per consensus guidelines, rechallenge may be considered only in patients who experienced Grade 1 ILD that completely resolved both clinically and radiographically. Higher grade ILD (Grade 2-4) is generally considered a contraindication to rechallenge. Anti-drug antibodies, HER2 status, skin testing, and baseline PFTs do not reliably predict ILD recurrence risk. The mechanism of T-DXd-associated ILD is not fully understood but appears related to the topoisomerase I inhibitor payload rather than immune-mediated hypersensitivity.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 58-year-old woman with metastatic HER2+ breast cancer who developed drug-induced ILD on trastuzumab deruxtecan (T-DXd), improved after discontinuation/steroids, but now has disease progression requiring treatment decisions. The question asks which factor most strongly supports rechallenge. Key discriminating findings: (1) ILD occurred and resolved, (2) disease progression necessitates treatment, (3) need to assess rechallenge safety. Option A correctly identifies that Grade 1 ILD with complete resolution is the primary factor supporting rechallenge per consensus guidelines and manufacturer recommendations. This is the established criterion for considering rechallenge with T-DXd. Option B (anti-drug antibodies) is irrelevant since T-DXd ILD is payload-related, not immune-mediated. Option C (HER2 amplification) addresses treatment efficacy but not rechallenge safety. Option D (skin testing) has no validated role in predicting ILD recurrence. Option E (baseline PFTs) doesn't predict ILD recurrence risk. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high, reflecting current oncology practice regarding T-DXd rechallenge. Minimal fix: None needed; item is well-constructed and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 58-year-old woman with metastatic HER2+ breast cancer who developed drug-induced ILD on trastuzumab deruxtecan (T-DXd), improved after discontinuation/steroids, but now has disease progression requiring treatment decisions. The question asks which factor most strongly supports rechallenge. Key discriminating findings: (1) ILD occurred and resolved, (2) disease progression necessitates treatment, (3) need to assess rechallenge safety. Option A correctly identifies that Grade 1 ILD with complete resolution is the primary factor supporting rechallenge per consensus guidelines and manufacturer recommendations. This is the established criterion for considering rechallenge with T-DXd. Option B (anti-drug antibodies) is irrelevant since T-DXd ILD is payload-related, not immune-mediated. Option C (HER2 amplification) addresses treatment efficacy but not rechallenge safety. Option D (skin testing) has no validated role in predicting ILD recurrence. Option E (baseline PFTs) doesn't predict ILD recurrence risk. The item is logically valid with one defensible best answer matching the key. Medical accuracy is high, reflecting current oncology practice regarding T-DXd rechallenge. Minimal fix: None needed; item is well-constructed and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-008", "question": "A 42-year-old woman with a history of chronic rhinosinusitis and nasal polyps presents with new-onset asthma requiring systemic corticosteroids. She reports severe reactions to aspirin and ibuprofen characterized by bronchospasm and nasal congestion. She requires hip replacement surgery and the orthopedic surgeon requests clearance for perioperative ketorolac use. After shared decision-making, aspirin desensitization is planned. During the desensitization protocol, she develops bronchospasm at the 60 mg aspirin dose. Which mediator's urinary metabolite would be most elevated during this reaction?", "options": ["Leukotriene E4", "Prostaglandin D2 (as 11β-prostaglandin F2α)", "Histamine (as N-methylhistamine)", "Tryptase", "Platelet-activating factor"], "answer": "A", "answer_index": 0, "explanation": "Aspirin-exacerbated respiratory disease (AERD) is characterized by overproduction of cysteinyl leukotrienes (CysLTs) due to dysregulated arachidonic acid metabolism. During aspirin-induced reactions in AERD, urinary leukotriene E4 (LTE4), the stable end-metabolite of CysLTs, increases dramatically (often 3-10 fold). This distinguishes AERD from IgE-mediated reactions where prostaglandin D2 metabolites and histamine metabolites predominate. Tryptase elevation suggests mast cell degranulation in anaphylaxis but is not characteristic of AERD reactions. The CysLT pathway is the primary driver of bronchoconstriction in AERD.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes classic aspirin-exacerbated respiratory disease (AERD, Samter's triad): chronic rhinosinusitis with nasal polyps, asthma, and aspirin/NSAID hypersensitivity with respiratory reactions. The question asks which urinary metabolite would be most elevated during the bronchospasm reaction at 60 mg aspirin during desensitization. Key discriminating findings: (1) AERD phenotype with respiratory reactions to aspirin/NSAIDs, (2) bronchospasm during aspirin challenge, (3) asking for urinary metabolite. In AERD, COX-1 inhibition by aspirin shifts arachidonic acid metabolism toward the 5-lipoxygenase pathway, causing massive overproduction of cysteinyl leukotrienes (LTC4, LTD4, LTE4). Urinary LTE4 is the stable end-metabolite and gold-standard biomarker for AERD reactions, increasing 3-10 fold during aspirin provocation. Alternative assessment: (B) PGD2 metabolite suggests mast cell activation in IgE-mediated reactions, not AERD's primary mechanism; (C) histamine metabolite also indicates IgE-mediated/mast cell reactions; (D) tryptase elevation is characteristic of anaphylaxis/mastocytosis, not AERD; (E) PAF lacks specific urinary metabolite monitoring in AERD. The item is medically accurate, logically sound, and tests appropriate knowledge of AERD pathophysiology. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes classic aspirin-exacerbated respiratory disease (AERD, Samter's triad): chronic rhinosinusitis with nasal polyps, asthma, and aspirin/NSAID hypersensitivity with respiratory reactions. The question asks which urinary metabolite would be most elevated during the bronchospasm reaction at 60 mg aspirin during desensitization. Key discriminating findings: (1) AERD phenotype with respiratory reactions to aspirin/NSAIDs, (2) bronchospasm during aspirin challenge, (3) asking for urinary metabolite. In AERD, COX-1 inhibition by aspirin shifts arachidonic acid metabolism toward the 5-lipoxygenase pathway, causing massive overproduction of cysteinyl leukotrienes (LTC4, LTD4, LTE4). Urinary LTE4 is the stable end-metabolite and gold-standard biomarker for AERD reactions, increasing 3-10 fold during aspirin provocation. Alternative assessment: (B) PGD2 metabolite suggests mast cell activation in IgE-mediated reactions, not AERD's primary mechanism; (C) histamine metabolite also indicates IgE-mediated/mast cell reactions; (D) tryptase elevation is characteristic of anaphylaxis/mastocytosis, not AERD; (E) PAF lacks specific urinary metabolite monitoring in AERD. The item is medically accurate, logically sound, and tests appropriate knowledge of AERD pathophysiology. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-009", "question": "An 82-year-old woman with moderate Alzheimer's dementia (MMSE 18) living in assisted living is hospitalized for community-acquired pneumonia. On hospital day 2, she becomes acutely agitated with visual hallucinations. Her medications include donepezil, memantine, and lisinopril. She is started on haloperidol 0.5 mg for agitation. On day 3, she develops temperature 39.2°C, severe muscle rigidity, diaphoresis, and altered consciousness. Laboratory studies show CK 8,500 U/L and WBC 14,000/μL. Which mechanism best explains this presentation?", "options": ["Anticholinergic toxicity from haloperidol-donepezil interaction", "Dopamine receptor blockade causing neuroleptic malignant syndrome", "Serotonin syndrome from memantine-haloperidol interaction", "Malignant hyperthermia triggered by infection", "Central fever from hypothalamic involvement by infection"], "answer": "B", "answer_index": 1, "explanation": "This patient has developed neuroleptic malignant syndrome (NMS) following haloperidol administration, characterized by the classic tetrad of hyperthermia, severe rigidity, altered mental status, and autonomic instability with elevated CK. Elderly patients with dementia are at increased risk for NMS. The mechanism is dopamine D2 receptor blockade in the hypothalamus and nigrostriatal pathways. While donepezil increases acetylcholine (potentially worsening extrapyramidal symptoms), the presentation is classic for NMS rather than anticholinergic toxicity. Memantine is an NMDA antagonist with minimal serotonergic activity, making serotonin syndrome unlikely.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes an 82-year-old woman with dementia who develops acute fever (39.2°C), severe muscle rigidity, diaphoresis, altered consciousness, and markedly elevated CK (8,500 U/L) on day 3 after starting haloperidol 0.5 mg for agitation. Key discriminating findings: (1) temporal relationship to haloperidol initiation, (2) classic tetrad of hyperthermia, rigidity, altered mental status, autonomic instability, (3) elevated CK indicating rhabdomyolysis, (4) elderly patient with dementia (high-risk population). This constellation is pathognomonic for neuroleptic malignant syndrome (NMS). Option B correctly identifies dopamine D2 receptor blockade as the mechanism. Alternative assessment: A is incorrect—anticholinergic toxicity presents with dry skin, mydriasis, urinary retention, not rigidity or elevated CK. C is implausible—memantine lacks significant serotonergic activity; serotonin syndrome features hyperreflexia and clonus, not lead-pipe rigidity. D (malignant hyperthermia) requires volatile anesthetics or succinylcholine exposure, absent here. E (central fever) would not explain rigidity or CK elevation. No logical flaws; stem provides sufficient detail for unique best answer. Medical accuracy is excellent—presentation, mechanism, and risk factors align with standard NMS teaching. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes an 82-year-old woman with dementia who develops acute fever (39.2°C), severe muscle rigidity, diaphoresis, altered consciousness, and markedly elevated CK (8,500 U/L) on day 3 after starting haloperidol 0.5 mg for agitation. Key discriminating findings: (1) temporal relationship to haloperidol initiation, (2) classic tetrad of hyperthermia, rigidity, altered mental status, autonomic instability, (3) elevated CK indicating rhabdomyolysis, (4) elderly patient with dementia (high-risk population). This constellation is pathognomonic for neuroleptic malignant syndrome (NMS). Option B correctly identifies dopamine D2 receptor blockade as the mechanism. Alternative assessment: A is incorrect—anticholinergic toxicity presents with dry skin, mydriasis, urinary retention, not rigidity or elevated CK. C is implausible—memantine lacks significant serotonergic activity; serotonin syndrome features hyperreflexia and clonus, not lead-pipe rigidity. D (malignant hyperthermia) requires volatile anesthetics or succinylcholine exposure, absent here. E (central fever) would not explain rigidity or CK elevation. No logical flaws; stem provides sufficient detail for unique best answer. Medical accuracy is excellent—presentation, mechanism, and risk factors align with standard NMS teaching. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-010", "question": "A 55-year-old man with cirrhosis secondary to alcohol use disorder and hepatocellular carcinoma (single 3.5 cm lesion, no vascular invasion, AFP 450 ng/mL) undergoes liver transplantation. Explant pathology confirms a single 3.8 cm moderately differentiated HCC without microvascular invasion. Eighteen months post-transplant, surveillance imaging reveals a 2.2 cm lung nodule. Biopsy confirms metastatic HCC. His current immunosuppression includes tacrolimus and mycophenolate mofetil. Which modification to his immunosuppressive regimen is most strongly supported by evidence for managing this recurrence?", "options": ["Conversion from tacrolimus to cyclosporine", "Addition of belatacept to current regimen", "Conversion from tacrolimus to sirolimus", "Discontinuation of all immunosuppression", "Addition of azathioprine to current regimen"], "answer": "C", "answer_index": 2, "explanation": "Conversion from calcineurin inhibitors (tacrolimus) to mTOR inhibitors (sirolimus/everolimus) is recommended in post-transplant HCC recurrence. mTOR inhibitors have direct antitumor effects through inhibition of the PI3K/AKT/mTOR pathway, which is frequently dysregulated in HCC. Multiple studies have shown improved outcomes with mTOR inhibitor-based immunosuppression in HCC recurrence. Complete immunosuppression withdrawal risks allograft rejection without proven oncologic benefit. Cyclosporine, belatacept, and azathioprine lack the antitumor properties of mTOR inhibitors.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes post-transplant HCC recurrence (lung metastasis 18 months post-liver transplant) in a patient on tacrolimus/mycophenolate. Key discriminating findings: confirmed metastatic HCC, current CNI-based immunosuppression, need to balance graft protection with oncologic management. The question asks for the evidence-supported immunosuppression modification. Option C (conversion to sirolimus) is the uniquely defensible best answer: mTOR inhibitors have documented antitumor effects via PI3K/AKT/mTOR pathway inhibition, and multiple studies support conversion from CNIs to mTOR inhibitors in post-transplant HCC recurrence while maintaining immunosuppression. Option A (cyclosporine) is another CNI without antitumor benefit. Option B (belatacept) lacks evidence for HCC benefit. Option D (complete withdrawal) risks rejection without proven oncologic advantage. Option E (azathioprine) has no antitumor properties. The medical reasoning aligns with current transplant oncology practice: mTOR inhibitor conversion is standard for post-transplant HCC recurrence. No logical flaws or missing critical details prevent unique answer selection. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes post-transplant HCC recurrence (lung metastasis 18 months post-liver transplant) in a patient on tacrolimus/mycophenolate. Key discriminating findings: confirmed metastatic HCC, current CNI-based immunosuppression, need to balance graft protection with oncologic management. The question asks for the evidence-supported immunosuppression modification. Option C (conversion to sirolimus) is the uniquely defensible best answer: mTOR inhibitors have documented antitumor effects via PI3K/AKT/mTOR pathway inhibition, and multiple studies support conversion from CNIs to mTOR inhibitors in post-transplant HCC recurrence while maintaining immunosuppression. Option A (cyclosporine) is another CNI without antitumor benefit. Option B (belatacept) lacks evidence for HCC benefit. Option D (complete withdrawal) risks rejection without proven oncologic advantage. Option E (azathioprine) has no antitumor properties. The medical reasoning aligns with current transplant oncology practice: mTOR inhibitor conversion is standard for post-transplant HCC recurrence. No logical flaws or missing critical details prevent unique answer selection. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-011", "question": "A 48-year-old woman with Crohn's disease on vedolizumab presents with 6 months of progressive fatigue, exertional dyspnea, and paresthesias in her feet. Laboratory studies reveal hemoglobin 8.2 g/dL, MCV 118 fL, reticulocyte count 1.2%, LDH 890 U/L, and indirect bilirubin 2.1 mg/dL. Peripheral smear shows macro-ovalocytes and hypersegmented neutrophils. Vitamin B12 level is 85 pg/mL (normal >200). Anti-intrinsic factor antibodies are negative. She has no history of gastric surgery. Upper endoscopy with gastric biopsy shows chronic atrophic gastritis with intestinal metaplasia but no Helicobacter pylori. Which additional finding would most strongly suggest an autoimmune etiology despite negative anti-IF antibodies?", "options": ["Elevated serum gastrin level >1000 pg/mL", "Presence of anti-parietal cell antibodies", "Low serum pepsinogen I with normal pepsinogen II", "Enterochromaffin-like cell hyperplasia on biopsy", "Positive anti-Saccharomyces cerevisiae antibodies"], "answer": "C", "answer_index": 2, "explanation": "Low serum pepsinogen I (PGI) with normal pepsinogen II (PGII), resulting in a low PGI/PGII ratio, is highly specific for corpus-predominant atrophic gastritis characteristic of autoimmune gastritis. PGI is produced exclusively by chief cells in the corpus, which are destroyed in autoimmune gastritis. Anti-IF antibodies have only 50-70% sensitivity for pernicious anemia. Anti-parietal cell antibodies are more sensitive but less specific. Elevated gastrin and ECL hyperplasia occur in autoimmune gastritis but are consequences rather than diagnostic markers. ASCA is associated with Crohn's disease, not autoimmune gastritis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 48-year-old woman with Crohn's disease presenting with megaloblastic anemia (MCV 118, macro-ovalocytes, hypersegmented neutrophils), B12 deficiency (85 pg/mL), and chronic atrophic gastritis with intestinal metaplasia. Key discriminating findings: negative anti-IF antibodies despite clinical picture consistent with pernicious anemia, and biopsy showing atrophic gastritis. The question asks which finding most strongly suggests autoimmune etiology despite negative anti-IF antibodies. Choice C (low PGI with normal PGII) is the best answer because pepsinogen I is produced exclusively by chief and mucous neck cells in the gastric corpus/fundus, which are specifically destroyed in autoimmune gastritis, making a low PGI/PGII ratio highly specific for corpus-predominant atrophic gastritis. Choice A (elevated gastrin) is a consequence of achlorhydria but occurs in any cause of atrophic gastritis. Choice B (anti-parietal cell antibodies) is more sensitive but less specific than the pepsinogen ratio. Choice D (ECL hyperplasia) is also a consequence of hypergastrinemia. Choice E (ASCA) relates to Crohn's disease, not autoimmune gastritis. The item is logically valid with appropriate discrimination between options. Minimal fix: None needed; item is well-constructed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 48-year-old woman with Crohn's disease presenting with megaloblastic anemia (MCV 118, macro-ovalocytes, hypersegmented neutrophils), B12 deficiency (85 pg/mL), and chronic atrophic gastritis with intestinal metaplasia. Key discriminating findings: negative anti-IF antibodies despite clinical picture consistent with pernicious anemia, and biopsy showing atrophic gastritis. The question asks which finding most strongly suggests autoimmune etiology despite negative anti-IF antibodies. Choice C (low PGI with normal PGII) is the best answer because pepsinogen I is produced exclusively by chief and mucous neck cells in the gastric corpus/fundus, which are specifically destroyed in autoimmune gastritis, making a low PGI/PGII ratio highly specific for corpus-predominant atrophic gastritis. Choice A (elevated gastrin) is a consequence of achlorhydria but occurs in any cause of atrophic gastritis. Choice B (anti-parietal cell antibodies) is more sensitive but less specific than the pepsinogen ratio. Choice D (ECL hyperplasia) is also a consequence of hypergastrinemia. Choice E (ASCA) relates to Crohn's disease, not autoimmune gastritis. The item is logically valid with appropriate discrimination between options. Minimal fix: None needed; item is well-constructed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-012", "question": "A 52-year-old man with IgA nephropathy and eGFR 35 mL/min/1.73m² is enrolled in a clinical trial evaluating a novel targeted-release formulation of budesonide (NEFECON). After 9 months of treatment, his 24-hour urine protein decreases from 2.8 g to 0.9 g, and eGFR stabilizes. Repeat kidney biopsy shows reduced mesangial IgA deposits and decreased mesangial hypercellularity. Which mechanism best explains the therapeutic effect of this formulation in IgA nephropathy?", "options": ["Systemic immunosuppression reducing circulating galactose-deficient IgA1", "Direct podocyte stabilization through glucocorticoid receptor activation", "Targeted delivery to Peyer's patches reducing mucosal IgA production", "Inhibition of complement activation at the glomerular level", "Suppression of bone marrow plasma cells producing pathogenic IgA1"], "answer": "C", "answer_index": 2, "explanation": "NEFECON (targeted-release budesonide) is formulated to release budesonide in the distal ileum where Peyer's patches are concentrated. The pathogenesis of IgA nephropathy involves mucosal immune dysregulation with production of galactose-deficient IgA1 (Gd-IgA1) primarily in gut-associated lymphoid tissue (GALT). By targeting Peyer's patches, NEFECON reduces the source of pathogenic Gd-IgA1 production while minimizing systemic corticosteroid exposure due to high first-pass hepatic metabolism. This mucosal-targeted approach distinguishes it from systemic immunosuppression strategies.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a patient with IgA nephropathy treated with targeted-release budesonide (NEFECON) showing clinical improvement. Key discriminating findings: (1) novel targeted-release formulation, (2) reduced proteinuria and stabilized eGFR, (3) decreased mesangial IgA deposits on biopsy. The question asks for the mechanism explaining therapeutic effect. Option C correctly identifies NEFECON's unique mechanism: targeted delivery to Peyer's patches in the distal ileum to reduce mucosal IgA production at its source in gut-associated lymphoid tissue (GALT), where galactose-deficient IgA1 originates. This aligns with established IgA nephropathy pathogenesis and NEFECON's design. Option A (systemic immunosuppression) is incorrect because NEFECON's targeted-release design specifically minimizes systemic exposure through first-pass hepatic metabolism. Option B (podocyte stabilization) is not the primary mechanism in IgA nephropathy treatment. Option D (complement inhibition) is not glucocorticoid's main action. Option E (bone marrow suppression) misidentifies the anatomic source of pathogenic IgA1, which is primarily mucosal (GALT), not bone marrow. The item is medically accurate, reflecting current understanding of IgA nephropathy pathogenesis and NEFECON's mechanism from clinical trials. No logical flaws or ambiguities present. Minimal fix: None needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a patient with IgA nephropathy treated with targeted-release budesonide (NEFECON) showing clinical improvement. Key discriminating findings: (1) novel targeted-release formulation, (2) reduced proteinuria and stabilized eGFR, (3) decreased mesangial IgA deposits on biopsy. The question asks for the mechanism explaining therapeutic effect. Option C correctly identifies NEFECON's unique mechanism: targeted delivery to Peyer's patches in the distal ileum to reduce mucosal IgA production at its source in gut-associated lymphoid tissue (GALT), where galactose-deficient IgA1 originates. This aligns with established IgA nephropathy pathogenesis and NEFECON's design. Option A (systemic immunosuppression) is incorrect because NEFECON's targeted-release design specifically minimizes systemic exposure through first-pass hepatic metabolism. Option B (podocyte stabilization) is not the primary mechanism in IgA nephropathy treatment. Option D (complement inhibition) is not glucocorticoid's main action. Option E (bone marrow suppression) misidentifies the anatomic source of pathogenic IgA1, which is primarily mucosal (GALT), not bone marrow. The item is medically accurate, reflecting current understanding of IgA nephropathy pathogenesis and NEFECON's mechanism from clinical trials. No logical flaws or ambiguities present. Minimal fix: None needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-013", "question": "A 67-year-old man with JAK2 V617F-positive polycythemia vera on hydroxyurea for 8 years presents with progressive splenomegaly, worsening anemia (hemoglobin 8.5 g/dL), and new circulating blasts (6%). Bone marrow biopsy shows 30% cellularity with grade 3 reticulin fibrosis, 8% blasts, and megakaryocyte clustering with atypia. Cytogenetics reveal del(5q), +8, and a new TP53 mutation is detected. Which statement most accurately characterizes his prognosis and optimal management?", "options": ["This represents post-PV myelofibrosis; ruxolitinib will improve survival", "This is post-PV acute myeloid leukemia; intensive chemotherapy is indicated", "This is accelerated phase disease; allogeneic transplant offers best survival", "The TP53 mutation predicts excellent response to hypomethylating agents", "Luspatercept should be initiated for the anemia before other interventions"], "answer": "C", "answer_index": 2, "explanation": "This patient has post-PV myelofibrosis in accelerated phase (10-19% blasts defines accelerated phase; ≥20% defines blast phase/AML). The presence of TP53 mutation, complex cytogenetics including del(5q), and high-risk features confer extremely poor prognosis. Allogeneic stem cell transplantation is the only potentially curative option, though outcomes remain poor with TP53 mutations. Ruxolitinib provides symptomatic benefit but does not improve survival in accelerated/blast phase. TP53 mutations predict poor response to hypomethylating agents and chemotherapy. Luspatercept addresses anemia but not the underlying disease progression.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient with JAK2+ PV on hydroxyurea presenting with splenomegaly, anemia, 6% circulating blasts, bone marrow with 8% blasts, fibrosis, complex cytogenetics (del(5q), +8), and TP53 mutation. Key discriminating findings: 8% BM blasts, TP53 mutation, complex karyotype, post-PV evolution with fibrosis. Main logical issue: The blast percentage (8%) creates ambiguity. Standard WHO criteria define post-PV AML as ≥20% blasts; 10-19% is accelerated phase. However, 8% blasts falls below the 10% threshold for accelerated phase by strict WHO definitions, yet the rationale claims this IS accelerated phase. This contradiction makes both B and C potentially defensible depending on interpretation. Option B could be defended if one considers the high-risk features (TP53, complex cytogenetics) as indicating imminent transformation requiring AML-directed therapy. Option C is keyed but requires accepting 8% as \\\"accelerated phase\\\" when it technically isn't by standard criteria. The medical accuracy is compromised by misclassifying 8% blasts as accelerated phase. Minimal fix: Change bone marrow blasts to 12-15% to unambiguously establish accelerated phase, making C the clear best answer.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient with JAK2+ PV on hydroxyurea presenting with splenomegaly, anemia, 6% circulating blasts, bone marrow with 8% blasts, fibrosis, complex cytogenetics (del(5q), +8), and TP53 mutation. Key discriminating findings: 8% BM blasts, TP53 mutation, complex karyotype, post-PV evolution with fibrosis. Main logical issue: The blast percentage (8%) creates ambiguity. Standard WHO criteria define post-PV AML as ≥20% blasts; 10-19% is accelerated phase. However, 8% blasts falls below the 10% threshold for accelerated phase by strict WHO definitions, yet the rationale claims this IS accelerated phase. This contradiction makes both B and C potentially defensible depending on interpretation. Option B could be defended if one considers the high-risk features (TP53, complex cytogenetics) as indicating imminent transformation requiring AML-directed therapy. Option C is keyed but requires accepting 8% as \"accelerated phase\" when it technically isn't by standard criteria. The medical accuracy is compromised by misclassifying 8% blasts as accelerated phase. Minimal fix: Change bone marrow blasts to 12-15% to unambiguously establish accelerated phase, making C the clear best answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-014", "question": "A 35-year-old man presents with recurrent bacterial sinopulmonary infections and chronic norovirus gastroenteritis. Laboratory evaluation reveals IgG 320 mg/dL, IgA 45 mg/dL, IgM 25 mg/dL, and absent specific antibody responses to pneumococcal polysaccharide and protein antigens despite vaccination. B-cell numbers are normal. Genetic testing reveals a heterozygous mutation in NFKB1. His 8-year-old daughter has similar symptoms. Which additional clinical manifestation is most characteristically associated with this genetic defect?", "options": ["Severe combined immunodeficiency in infancy", "Autoimmune cytopenias and lymphoproliferation", "Hyper-IgE syndrome with eczema and bone abnormalities", "Complement deficiency with recurrent Neisseria infections", "Chronic granulomatous disease with catalase-positive organisms"], "answer": "B", "answer_index": 1, "explanation": "NFKB1 haploinsufficiency is an autosomal dominant cause of common variable immunodeficiency (CVID). Beyond hypogammaglobulinemia and recurrent infections, NFKB1 deficiency is strongly associated with autoimmune manifestations, particularly autoimmune cytopenias (autoimmune hemolytic anemia, ITP) and lymphoproliferation including splenomegaly and lymphadenopathy. NF-κB signaling is critical for B-cell survival, class-switch recombination, and immune tolerance. The autosomal dominant inheritance pattern explains the affected daughter. SCID, hyper-IgE, complement deficiency, and CGD have distinct genetic etiologies and clinical presentations.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 35-year-old man with hypogammaglobulinemia (low IgG, IgA, IgM), absent vaccine responses, recurrent sinopulmonary infections, chronic norovirus gastroenteritis, normal B-cell numbers, and heterozygous NFKB1 mutation with autosomal dominant inheritance (affected daughter). Key discriminating findings: (1) CVID phenotype with hypogammaglobulinemia and impaired antibody responses despite normal B-cell numbers; (2) heterozygous NFKB1 mutation; (3) autosomal dominant pattern. NFKB1 haploinsufficiency causes CVID with characteristic autoimmune complications. Option B (autoimmune cytopenias and lymphoproliferation) is the established association—NF-κB pathway defects impair immune tolerance and B-cell regulation, leading to autoimmune hemolytic anemia, ITP, splenomegaly, and lymphadenopathy in 40-60% of NFKB1-deficient patients. Alternative assessment: A (SCID) contradicts normal B-cells and survival to age 35; C (hyper-IgE) requires STAT3/DOCK8 mutations with elevated IgE and eczema, not present; D (complement deficiency) has normal immunoglobulin levels; E (CGD) involves phagocyte oxidative burst defects with NADPH oxidase mutations, unrelated to NFKB1. The item is logically valid with strong stem-to-answer alignment. Medical accuracy is excellent—reflects current understanding of NFKB1-associated CVID. Minimal fix: none needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 35-year-old man with hypogammaglobulinemia (low IgG, IgA, IgM), absent vaccine responses, recurrent sinopulmonary infections, chronic norovirus gastroenteritis, normal B-cell numbers, and heterozygous NFKB1 mutation with autosomal dominant inheritance (affected daughter). Key discriminating findings: (1) CVID phenotype with hypogammaglobulinemia and impaired antibody responses despite normal B-cell numbers; (2) heterozygous NFKB1 mutation; (3) autosomal dominant pattern. NFKB1 haploinsufficiency causes CVID with characteristic autoimmune complications. Option B (autoimmune cytopenias and lymphoproliferation) is the established association—NF-κB pathway defects impair immune tolerance and B-cell regulation, leading to autoimmune hemolytic anemia, ITP, splenomegaly, and lymphadenopathy in 40-60% of NFKB1-deficient patients. Alternative assessment: A (SCID) contradicts normal B-cells and survival to age 35; C (hyper-IgE) requires STAT3/DOCK8 mutations with elevated IgE and eczema, not present; D (complement deficiency) has normal immunoglobulin levels; E (CGD) involves phagocyte oxidative burst defects with NADPH oxidase mutations, unrelated to NFKB1. The item is logically valid with strong stem-to-answer alignment. Medical accuracy is excellent—reflects current understanding of NFKB1-associated CVID. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-015", "question": "A 45-year-old woman from rural Peru presents with a 3-month history of progressive dysphagia, regurgitation, and 20-pound weight loss. Barium swallow shows a dilated esophagus with smooth tapering at the gastroesophageal junction (\"bird's beak\" appearance). Esophageal manometry reveals absent peristalsis and incomplete lower esophageal sphincter relaxation. Serologic testing for Trypanosoma cruzi is positive. Cardiac evaluation shows a dilated left ventricle with apical aneurysm and EF 35%. Which statement best characterizes the pathophysiology linking her esophageal and cardiac findings?", "options": ["Direct parasitic invasion of smooth muscle cells in both organs", "Autoimmune destruction of intramural neurons and cardiac myocytes", "Eosinophilic infiltration causing tissue fibrosis", "Vasculitis affecting the vasa nervorum and coronary arteries", "Toxin-mediated damage similar to diphtheria"], "answer": "B", "answer_index": 1, "explanation": "Chronic Chagas disease (American trypanosomiasis) causes megaesophagus and cardiomyopathy through autoimmune mechanisms. Molecular mimicry between T. cruzi antigens and host cardiac myosin, neuronal proteins, and other self-antigens triggers autoimmune destruction of intramural ganglion cells (Auerbach's plexus) in the esophagus and cardiac myocytes/conduction tissue. The apical aneurysm is pathognomonic for Chagas cardiomyopathy. Direct parasitic invasion occurs in acute phase but parasites are rarely found in chronic lesions. The pathology is characterized by lymphocytic infiltration and fibrosis, not eosinophilia or vasculitis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes classic chronic Chagas disease with megaesophagus (bird's beak, absent peristalsis, incomplete LES relaxation) and Chagas cardiomyopathy (dilated LV, apical aneurysm—pathognomonic). Key discriminating findings: positive T. cruzi serology, endemic region (rural Peru), characteristic esophageal and cardiac manifestations. The question asks about pathophysiology linking both organ systems. Option B correctly identifies autoimmune destruction of intramural neurons (Auerbach's plexus causing megaesophagus) and cardiac myocytes (causing cardiomyopathy) via molecular mimicry between T. cruzi antigens and host proteins. This is the established mechanism in chronic Chagas disease. Option A is incorrect—direct parasitic invasion occurs in acute phase but parasites are rarely found in chronic lesions where autoimmune mechanisms predominate. Options C, D, E describe unrelated pathophysiologic mechanisms not characteristic of Chagas disease. Medical accuracy: The item accurately reflects current understanding of chronic Chagas pathophysiology, correctly distinguishing acute (parasitic invasion) from chronic (autoimmune) mechanisms. The apical aneurysm detail strengthens diagnostic specificity. No medical inaccuracies identified. Minimal fix: None needed; item is logically valid and medically accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes classic chronic Chagas disease with megaesophagus (bird's beak, absent peristalsis, incomplete LES relaxation) and Chagas cardiomyopathy (dilated LV, apical aneurysm—pathognomonic). Key discriminating findings: positive T. cruzi serology, endemic region (rural Peru), characteristic esophageal and cardiac manifestations. The question asks about pathophysiology linking both organ systems. Option B correctly identifies autoimmune destruction of intramural neurons (Auerbach's plexus causing megaesophagus) and cardiac myocytes (causing cardiomyopathy) via molecular mimicry between T. cruzi antigens and host proteins. This is the established mechanism in chronic Chagas disease. Option A is incorrect—direct parasitic invasion occurs in acute phase but parasites are rarely found in chronic lesions where autoimmune mechanisms predominate. Options C, D, E describe unrelated pathophysiologic mechanisms not characteristic of Chagas disease. Medical accuracy: The item accurately reflects current understanding of chronic Chagas pathophysiology, correctly distinguishing acute (parasitic invasion) from chronic (autoimmune) mechanisms. The apical aneurysm detail strengthens diagnostic specificity. No medical inaccuracies identified. Minimal fix: None needed; item is logically valid and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-016", "question": "A 62-year-old man with metastatic melanoma harboring BRAF V600E mutation has disease progression on combination dabrafenib/trametinib after 14 months. He is started on pembrolizumab. After 4 cycles, restaging shows mixed response with regression of most lesions but growth of a single hepatic metastasis. Biopsy of the progressing lesion reveals loss of β2-microglobulin expression. Which mechanism best explains resistance to pembrolizumab in this lesion?", "options": ["Upregulation of alternative immune checkpoints (LAG-3, TIM-3)", "Defective antigen presentation via MHC class I pathway", "Increased regulatory T-cell infiltration in the tumor microenvironment", "Activation of the WNT/β-catenin pathway excluding T-cells", "Loss of tumor neoantigens through immunoediting"], "answer": "B", "answer_index": 1, "explanation": "β2-microglobulin (B2M) is essential for MHC class I complex assembly and surface expression. Loss of B2M results in absent MHC class I expression, preventing CD8+ T-cell recognition of tumor antigens regardless of PD-1/PD-L1 blockade. This is a well-characterized mechanism of acquired resistance to checkpoint inhibitors. While alternative checkpoints, Tregs, WNT/β-catenin activation, and neoantigen loss can all contribute to immunotherapy resistance, the specific finding of B2M loss directly implicates defective MHC class I antigen presentation as the primary resistance mechanism in this lesion.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a patient with metastatic melanoma on pembrolizumab (anti-PD-1) showing mixed response, with biopsy of a progressing lesion revealing loss of β2-microglobulin (B2M) expression. Key discriminating finding: B2M loss is the specific molecular abnormality identified. B2M is essential for MHC class I assembly and surface expression; its loss prevents CD8+ T-cells from recognizing tumor antigens, rendering PD-1 blockade ineffective regardless of checkpoint status. This directly points to option B (defective MHC class I antigen presentation) as the mechanism. Alternative options represent other valid resistance mechanisms but lack the direct mechanistic link to the specific finding: A (alternative checkpoints) would not be indicated by B2M loss; C (Tregs) is nonspecific; D (WNT/β-catenin) can exclude T-cells but is not directly tied to B2M loss; E (neoantigen loss) would not specifically cause B2M loss. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent, reflecting well-established immunotherapy resistance mechanisms. No fix needed.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a patient with metastatic melanoma on pembrolizumab (anti-PD-1) showing mixed response, with biopsy of a progressing lesion revealing loss of β2-microglobulin (B2M) expression. Key discriminating finding: B2M loss is the specific molecular abnormality identified. B2M is essential for MHC class I assembly and surface expression; its loss prevents CD8+ T-cells from recognizing tumor antigens, rendering PD-1 blockade ineffective regardless of checkpoint status. This directly points to option B (defective MHC class I antigen presentation) as the mechanism. Alternative options represent other valid resistance mechanisms but lack the direct mechanistic link to the specific finding: A (alternative checkpoints) would not be indicated by B2M loss; C (Tregs) is nonspecific; D (WNT/β-catenin) can exclude T-cells but is not directly tied to B2M loss; E (neoantigen loss) would not specifically cause B2M loss. The item is logically valid with a unique best answer matching the key. Medical accuracy is excellent, reflecting well-established immunotherapy resistance mechanisms. No fix needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-017", "question": "A 28-year-old woman with allergic rhinitis and mild persistent asthma on fluticasone/salmeterol presents for evaluation of recurrent anaphylaxis. She has experienced three episodes of anaphylaxis in the past year, each occurring 2-4 hours after eating, with no consistent food trigger identified. Episodes are characterized by flushing, hypotension, and abdominal cramping. Baseline serum tryptase is 6 ng/mL (normal <11.4). Skin prick testing to common food allergens is negative. During her most recent episode, serum tryptase was 28 ng/mL. Bone marrow biopsy shows scattered atypical mast cells expressing CD25. KIT D816V mutation is detected. Which diagnostic criterion confirms systemic mastocytosis in this patient?", "options": ["Elevated acute tryptase level during anaphylaxis", "Presence of CD25-positive mast cells on bone marrow biopsy", "Detection of KIT D816V mutation", "Baseline tryptase level above 20 ng/mL", "Multifocal dense mast cell aggregates (>15 mast cells) in bone marrow"], "answer": "E", "answer_index": 4, "explanation": "Diagnosis of systemic mastocytosis requires either the major criterion (multifocal dense aggregates of ≥15 mast cells in bone marrow or extracutaneous tissue) OR three minor criteria. Minor criteria include: >25% spindle-shaped/atypical mast cells, KIT D816V mutation, CD25/CD2 expression on mast cells, and baseline tryptase >20 ng/mL. This patient has two minor criteria (CD25 expression and KIT mutation) but needs either the major criterion or one more minor criterion. Her baseline tryptase of 6 ng/mL does not meet the minor criterion threshold. Finding dense mast cell aggregates (major criterion) would definitively confirm the diagnosis.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - option C is the correct best answer, not E. The question asks which criterion \\\"confirms\\\" systemic mastocytosis in THIS patient. Key stem clues: baseline tryptase 6 ng/mL (below 20 threshold), bone marrow shows CD25+ atypical mast cells, KIT D816V detected. The patient already has TWO minor criteria documented (CD25 expression on mast cells, KIT D816V mutation). Per WHO criteria, systemic mastocytosis requires 1 major + 1 minor criterion OR 3 minor criteria. Since the patient has 2 minor criteria, she needs either the major criterion OR one additional minor criterion to confirm diagnosis. Option E (major criterion) would confirm diagnosis, but option C (KIT D816V) is ALREADY present per the stem (\\\"KIT D816V mutation is detected\\\"). The question asks which criterion \\\"confirms\\\" - meaning which finding establishes the diagnosis. Since KIT D816V is already documented, it IS one of the confirming criteria. The item conflates \\\"what additional finding is needed\\\" with \\\"what confirms.\\\" Medical accuracy issue: The rationale correctly explains WHO criteria but misinterprets the question's ask. Minimal fix: Rephrase to \\\"Which ADDITIONAL finding would confirm systemic mastocytosis\\\" or remove KIT D816V from the stem and make it the answer.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - option C is the correct best answer, not E. The question asks which criterion \"confirms\" systemic mastocytosis in THIS patient. Key stem clues: baseline tryptase 6 ng/mL (below 20 threshold), bone marrow shows CD25+ atypical mast cells, KIT D816V detected. The patient already has TWO minor criteria documented (CD25 expression on mast cells, KIT D816V mutation). Per WHO criteria, systemic mastocytosis requires 1 major + 1 minor criterion OR 3 minor criteria. Since the patient has 2 minor criteria, she needs either the major criterion OR one additional minor criterion to confirm diagnosis. Option E (major criterion) would confirm diagnosis, but option C (KIT D816V) is ALREADY present per the stem (\"KIT D816V mutation is detected\"). The question asks which criterion \"confirms\" - meaning which finding establishes the diagnosis. Since KIT D816V is already documented, it IS one of the confirming criteria. The item conflates \"what additional finding is needed\" with \"what confirms.\" Medical accuracy issue: The rationale correctly explains WHO criteria but misinterprets the question's ask. Minimal fix: Rephrase to \"Which ADDITIONAL finding would confirm systemic mastocytosis\" or remove KIT D816V from the stem and make it the answer.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130", "question_id": "20251218T014545383Z_claude-opus-4-5-20251101_seed130-018", "question": "An 85-year-old man with heart failure with preserved ejection fraction, chronic kidney disease stage 3b, and type 2 diabetes is hospitalized for acute decompensated heart failure. He is treated with IV diuretics with good response. Prior to discharge, his medications are reviewed. His current regimen includes lisinopril 10 mg daily, metoprolol succinate 50 mg daily, empagliflozin 10 mg daily, and furosemide 40 mg twice daily. His eGFR is 38 mL/min/1.73m², potassium 4.8 mEq/L, and NT-proBNP 1,850 pg/mL (down from 5,200 on admission). Which medication adjustment is most strongly supported by evidence to reduce mortality in this patient?", "options": ["Add spironolactone 25 mg daily", "Increase lisinopril to 20 mg daily", "Add sacubitril/valsartan in place of lisinopril", "Add finerenone 10 mg daily", "Continue current regimen without changes"], "answer": "A", "answer_index": 0, "explanation": "The TOPCAT trial (Americas cohort) demonstrated mortality benefit with spironolactone in HFpEF. More importantly, the 2023 focused update to HF guidelines recommends MRAs (spironolactone/eplerenone) as a Class IIa recommendation for HFpEF to reduce hospitalizations. While finerenone has shown benefits in diabetic kidney disease, its role in HFpEF is less established than traditional MRAs. Sacubitril/valsartan (PARAGON-HF) showed benefit primarily in women and those with EF at the lower end of the HFpEF spectrum. With potassium 4.8 and eGFR 38, spironolactone can be safely initiated with monitoring. SGLT2 inhibitor is already optimized.", "generator_model": "claude-opus-4-5-20251101", "seed": 130, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes an 85-year-old with HFpEF, CKD 3b (eGFR 38), diabetes, K+ 4.8, already on empagliflozin. Key discriminating findings: HFpEF diagnosis, already on SGLT2i, borderline hyperkalemia with moderate CKD. The question asks which medication adjustment is \\\"most strongly supported by evidence to reduce mortality.\\\" Option A (spironolactone): TOPCAT Americas showed mortality benefit, but the trial had significant limitations (high placebo contamination, regional heterogeneity). Current guidelines give MRAs Class IIa for HFpEF primarily for hospitalization reduction, NOT mortality. The rationale overstates mortality evidence. Option D (finerenone): FINEARTS-HF (2024) demonstrated mortality and hospitalization benefit in HFpEF across the spectrum, with better safety profile than spironolactone in CKD/hyperkalemia. This is newer evidence than cited in the rationale. Both A and D are defensible; finerenone may actually be superior given the patient's CKD 3b and K+ 4.8. The item is underspecified regarding which guideline year/evidence base to apply, leading to multiple defensible answers. Medical accuracy issue: rationale incorrectly emphasizes mortality benefit for spironolactone in HFpEF when evidence is primarily for hospitalization. Minimal fix: specify guideline year (pre-2024) or change question to \\\"hospitalization reduction\\\" rather than mortality.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes an 85-year-old with HFpEF, CKD 3b (eGFR 38), diabetes, K+ 4.8, already on empagliflozin. Key discriminating findings: HFpEF diagnosis, already on SGLT2i, borderline hyperkalemia with moderate CKD. The question asks which medication adjustment is \"most strongly supported by evidence to reduce mortality.\" Option A (spironolactone): TOPCAT Americas showed mortality benefit, but the trial had significant limitations (high placebo contamination, regional heterogeneity). Current guidelines give MRAs Class IIa for HFpEF primarily for hospitalization reduction, NOT mortality. The rationale overstates mortality evidence. Option D (finerenone): FINEARTS-HF (2024) demonstrated mortality and hospitalization benefit in HFpEF across the spectrum, with better safety profile than spironolactone in CKD/hyperkalemia. This is newer evidence than cited in the rationale. Both A and D are defensible; finerenone may actually be superior given the patient's CKD 3b and K+ 4.8. The item is underspecified regarding which guideline year/evidence base to apply, leading to multiple defensible answers. Medical accuracy issue: rationale incorrectly emphasizes mortality benefit for spironolactone in HFpEF when evidence is primarily for hospitalization. Minimal fix: specify guideline year (pre-2024) or change question to \"hospitalization reduction\" rather than mortality.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}]